Track topics on Twitter Track topics that are important to you
Domain Therapeutics S.A. (Strasbourg, France) said it launched single-asset, U.K.-based Parkinson's disease newco Mavalon Therapeutics with an investment of up to EUR 9 million ($9.9 million) from Medicxi Ventures.
According to Domain, Mavalon will develop a positive allosteric modulator of metabotropic glutamate receptor subtype 3 (mGluR3, GRM3). Domain added that the compound is the first orally available small molecule to increase production of glial cell line-derived neurotrophic factor (GDNF) within PD patients' brains. Domain did not respond to inquiries.
Original Article: Domain launches PD newco MavalonNEXT ARTICLE
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...